Search

Displaying results 1691 - 1700 of 10000 in total
  1. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p683) … An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.

  2. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  3. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023.

  4. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    It is an antiviral agent that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. … As a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, it disrupts the replication of the virus through an antisense mechanism [L1428]

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

  6. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

    Products: Skyrizi 75 mg solution for injection in pre-filled syringe, Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET
  7. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the

  8. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … Dosulepin inhibits the reuptake of biogenic amines, increasing available neurotransmitter levels at the synaptic cleft.

    Synonyms: (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine, 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepinProducts: ESPIN CAPSULE 25 mg
  9. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … Human papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  10. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% E